

①-

Ram R. Shukla, Ph.D.

## ACTION SUMMARY FOR APPLICATION:

S/N: 09/043,665

Date of Action: 4/26/01

Oath/Declaration: OK

Priority: OK/9519776.0 Britain Sept 1995 (Priority Document Present)  
371

Drawings: No checked by Draft's man

### Action:

1. Claims pending 1-8, 11-21
2. Claims withdrawn 13-21
3. Claims canceled 9, 10
4. Claims under consideration 1-8, 11-12
5. Claims objected - None
6. Claims rejected 1-8, 11-12
7. 101 utility: None
8. 112 first para enablement: 1-8
9. 112 first para written description None
10. 112 2<sup>nd</sup> para 1-8, 11-12
11. 102 1-4, 11-12
12. 103 1-8, 11-12

### Other:

### Notes:

Claim 1 reads on both in vivo / invitro ; in vivo not enabled.  
1 no nexus between the preamble and the body of the claim.  
quiescent cells -? which have never divided  
or which went in senescence

112 2nd: how can growth factor be expressed on the surface of cell line  
112 2nd on cell line carry a vector - retroviral packaging cell line / genome of the cells  
claim - 5 - viral envelope protein ; retroviral envelope protein  
112 11 - surface bound growth factor - no antecedent basis  
claim 7 - antecedent basis for envelope

09 043065

371

~~09 043065~~  
~~5/15/78~~

I 1-10 Method of sampling cells (in vitro)

II 11-21 In Vivo Therapy (human)

→ I 1-12

→ II 13-21

① 

1	2	3	4	5	6	7	8	9	10	11	12
---	---	---	---	---	---	---	---	---	----	----	----


New Number for Attorney

206-695-1718

Talked to Dennis Shelton  
He will call Buehl

In writing

1/11/01



Method

Class I

In vitro transduction

using Retrovirus

vs

packaging cells for infection

Big issue?

Kathleen Williams  
Mark Fitzgerald.